Blood Group Typing Market by Product (Consumables, Instruments, Services), Test Type (ABO, Antigen, Antibody, HLA), Technique (Assay-based, PCR, Microarray, Massively Parallel Sequencing), End User (Hospital, Blood Banks), Region - Global Forecast to 2028
The blood group typing market is valued at an estimated USD 2.0 billion in 2023 and is projected to reach USD 3.0 billion by 2028, at a CAGR of 8.7% during the forecast period. Severe post-partum hemorrhage (bleeding during delivery or after childbirth) is the leading cause of maternal mortality worldwide. Additionally, childhood anemia, trauma, and congenital blood disorders are other emergency conditions requiring blood transfusions. Urgent and timely treatment is required to manage these patients, including transfusion of blood and blood products. The overall increase in the number of blood transfusions is leading to the increased adoption of blood group typing methods in order to ensure the safety and compatibility of the transfused blood. This is driving the overall growth of the market.
“Antibody screening segment accounted for the highest growth rate in the blood group typing market, by test type, during the forecast period.”
The blood group typing market is bifurcated into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing on the basis of test type. The antibody screening segment in the blood group typing market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as autoimmune disorders and cancers. The use of antibody screening methods is also growing due to the rising focus on R&D in antigen-specific therapies in response to the increasing incidence of chronic diseases.
“PCR-based and microarray techniques segment accounted for the highest growth rate in the blood group typing market, by techniques, during the forecast period.”
The global blood group typing market is bifurcated into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. The PCR-based and microarray techniques segment is currently witnessing the highest growth rate within the blood group typing market. PCR-based techniques have emerged as powerful tools to accurately identify and characterize rare blood group antigens at the genetic level. However, PCR methods have limited throughput and multiplex capacity. To overcome these limitations, microarray platforms have been developed. Microarray platforms give more detailed information about blood group antigens than basic PCR methods. Owing to the advantages of these methods, such as high accuracy over traditional methods, their adoption is increasing among end users.
“Asia Pacific: The fastest-growing region blood group typing market”
The global blood group typing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as government efforts to increase awareness about the importance of blood donations and regular health check-ups, continuously rising healthcare expenditures, an increasing number of hospitals in India and China, and strengthening research bases for diagnostic procedures across India, China, and Japan. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.
The break-up of the profile of primary participants in the blood group typing market:
Research Coverage:
This research report categorizes the blood group typing market by product & service (consumables, instruments, and services & software), test type (ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing), technique (assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques), end user (hospitals, blood banks, clinical laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, and opportunities, influencing the growth of the blood group typing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the blood group typing market. Competitive analysis of upcoming startups in the blood group typing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood group typing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, and opportunities.
The report provides insights on the following pointers:
“Antibody screening segment accounted for the highest growth rate in the blood group typing market, by test type, during the forecast period.”
The blood group typing market is bifurcated into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing on the basis of test type. The antibody screening segment in the blood group typing market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as autoimmune disorders and cancers. The use of antibody screening methods is also growing due to the rising focus on R&D in antigen-specific therapies in response to the increasing incidence of chronic diseases.
“PCR-based and microarray techniques segment accounted for the highest growth rate in the blood group typing market, by techniques, during the forecast period.”
The global blood group typing market is bifurcated into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. The PCR-based and microarray techniques segment is currently witnessing the highest growth rate within the blood group typing market. PCR-based techniques have emerged as powerful tools to accurately identify and characterize rare blood group antigens at the genetic level. However, PCR methods have limited throughput and multiplex capacity. To overcome these limitations, microarray platforms have been developed. Microarray platforms give more detailed information about blood group antigens than basic PCR methods. Owing to the advantages of these methods, such as high accuracy over traditional methods, their adoption is increasing among end users.
“Asia Pacific: The fastest-growing region blood group typing market”
The global blood group typing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as government efforts to increase awareness about the importance of blood donations and regular health check-ups, continuously rising healthcare expenditures, an increasing number of hospitals in India and China, and strengthening research bases for diagnostic procedures across India, China, and Japan. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.
The break-up of the profile of primary participants in the blood group typing market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
Research Coverage:
This research report categorizes the blood group typing market by product & service (consumables, instruments, and services & software), test type (ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing), technique (assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques), end user (hospitals, blood banks, clinical laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, and opportunities, influencing the growth of the blood group typing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the blood group typing market. Competitive analysis of upcoming startups in the blood group typing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood group typing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations, growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions, increasing demand for blood group typing in prenatal testing, high usage of blood group typing in forensic sciences, extensive R&D in blood typing, and stringent regulatory standards for blood transfusion), restraints (emergence of blood alternatives), and opportunities (growth opportunities in emerging economies) influencing the growth of the blood group typing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the blood group typing market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the blood group typing market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood group typing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US), among others in the blood group typing market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 BLOOD GROUP TYPING MARKET
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 BLOOD GROUP TYPING MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 BLOOD GROUP TYPING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: BLOOD GROUP TYPING MARKET
2.9 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 8 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE,
2023 VS. 2028 (USD MILLION)
FIGURE 9 BLOOD GROUP TYPING MARKET, BY TEST TYPE,
2023 VS. 2028 (USD MILLION)
FIGURE 10 BLOOD GROUP TYPING MARKET, BY TECHNIQUE,
2023 VS. 2028 (USD MILLION)
FIGURE 11 BLOOD GROUP TYPING MARKET, BY END USER,
2023 VS. 2028 (USD MILLION)
FIGURE 12 BLOOD GROUP TYPING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 BLOOD GROUP TYPING MARKET OVERVIEW
FIGURE 13 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 14 CONSUMABLES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2023 VS. 2028
FIGURE 15 ABO BLOOD TESTS & RH TYPING SEGMENT TO DOMINATE MARKET IN 2028
4.4 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2023 VS. 2028
FIGURE 16 ASSAY-BASED TECHNIQUES SEGMENT TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD
4.5 BLOOD GROUP TYPING MARKET, BY END USER, 2023 VS. 2028
FIGURE 17 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.6 BLOOD GROUP TYPING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN BLOOD GROUP TYPING MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 BLOOD GROUP TYPING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations
FIGURE 20 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 2015–2030 (MILLION INDIVIDUALS)
5.2.1.2 Growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions
5.2.1.3 Increasing demand for blood group typing in prenatal testing
5.2.1.4 High usage of blood group typing in forensic sciences
5.2.1.5 Extensive R&D in blood typing
5.2.1.6 Stringent regulatory standards for blood transfusion
TABLE 1 LIST OF PRODUCTS CBER REGULATES
5.2.2 RESTRAINTS
5.2.2.1 Emergence of blood alternatives
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
TABLE 2 INDICATIVE PRICING FOR BLOOD GROUP TYPING PRODUCTS
5.3.2 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 21 PATENT ANALYSIS FOR BLOOD GROUP TYPING REAGENTS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS OF BLOOD GROUP TYPING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 23 BLOOD GROUP TYPING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 24 BLOOD GROUP TYPING MARKET: ECOSYSTEM ANALYSIS
5.7.1 BLOOD GROUP TYPING MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 BLOOD GROUP TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY LANDSCAPE
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.5 MIDDLE EAST
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2023–2024
TABLE 13 BLOOD GROUP TYPING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 REVENUE SHIFT IN BLOOD GROUP TYPING MARKET
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS
TABLE 14 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
TABLE 15 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
5.15.3 CASE STUDY ANALYSIS
6 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 16 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
TABLE 17 KEY CONSUMABLES AVAILABLE IN MARKET
TABLE 18 BLOOD GROUP TYPING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 19 BLOOD GROUP TYPING CONSUMABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2.1 ANTISERA REAGENTS
6.2.1.1 Increasing demand for cost-effective blood typing solutions to support uptake of antisera reagents
TABLE 20 ANTISERA REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.2 ANTI-HUMAN GLOBULIN REAGENTS
6.2.2.1 Increasing number of organ transplantations to drive uptake of AHG reagents
TABLE 21 ANTI-HUMAN GLOBULIN REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.3 RED BLOOD CELL REAGENTS
6.2.3.1 Higher compatibility of red blood cell reagents with variety of blood group typing techniques to support uptake
TABLE 22 RED BLOOD CELL REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.4 BLOOD BANK SALINE
6.2.4.1 Ability of blood bank saline to preserve integrity of RBCs to support market growth
TABLE 23 BLOOD BANK SALINE MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 GROWING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST DEMAND FOR BLOOD GROUP TYPING INSTRUMENTS
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 25 BLOOD GROUP TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN MARKET SEGMENT
TABLE 26 BLOOD GROUP TYPING SERVICES & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 BLOOD GROUP TYPING MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 27 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
7.2 ABO BLOOD TESTS & RH TYPING
7.2.1 GROWING AWARENESS OF IMPORTANCE OF BLOOD DONATION TO DRIVE GROWTH
TABLE 28 BLOOD GROUP TYPING MARKET FOR ABO BLOOD TESTS & RH TYPING, BY REGION, 2021–2028 (USD MILLION)
7.3 ANTIBODY SCREENING
7.3.1 INCREASING INCIDENCE OF CANCER AND AUTOIMMUNE DISORDERS TO SUPPORT GROWTH
TABLE 29 BLOOD GROUP TYPING MARKET FOR ANTIBODY SCREENING, BY REGION, 2021–2028 (USD MILLION)
7.4 HLA TYPING
7.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO STIMULATE DEMAND FOR HLA TYPING
TABLE 30 BLOOD GROUP TYPING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION)
7.5 CROSS-MATCHING TESTS
7.5.1 GROWING NEED FOR BLOOD TRANSFUSION TO PROPEL MARKET GROWTH
TABLE 31 BLOOD GROUP TYPING MARKET FOR CROSS-MATCHING TESTS, BY REGION, 2021–2028 (USD MILLION)
7.6 ANTIGEN TYPING
7.6.1 INCREASING CASES OF INCORRECT BLOOD TRANSFUSION TO FUEL GROWTH
TABLE 32 BLOOD GROUP TYPING MARKET FOR ANTIGEN TYPING, BY REGION, 2021–2028 (USD MILLION)
8 BLOOD GROUP TYPING MARKET, BY TECHNIQUE
8.1 INTRODUCTION
TABLE 33 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
8.2 ASSAY-BASED TECHNIQUES
8.2.1 AUTOMATION, SENSITIVITY, OBJECTIVITY, AND ADAPTABILITY OF ASSAY-BASED TECHNIQUES TO BOOST ADOPTION
TABLE 34 BLOOD GROUP TYPING MARKET FOR ASSAY-BASED TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
8.3 PCR-BASED AND MICROARRAY TECHNIQUES
8.3.1 HIGH ACCURACY OF PCR-BASED AND MICROARRAY TECHNIQUES TO SUPPORT GROWTH
TABLE 35 BLOOD GROUP TYPING MARKET FOR PCR-BASED AND MICROARRAY TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
8.4 MASSIVELY PARALLEL SEQUENCING
8.4.1 ABILITY TO DETECT LOW-FREQUENCY ALLELES TO DRIVE DEMAND FOR MPS TECHNIQUES
TABLE 36 BLOOD GROUP TYPING MARKET FOR MASSIVELY PARALLEL SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER TECHNIQUES
TABLE 37 BLOOD GROUP TYPING MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
9 BLOOD GROUP TYPING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 38 BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PRIMARY NOTES
9.2.1 KEY PRIMARY INSIGHTS
9.3 HOSPITALS
9.3.1 INCREASING NUMBER OF HOSPITALS TO BOOST GROWTH
TABLE 39 BLOOD GROUP TYPING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.4 BLOOD BANKS
9.4.1 GROWING NUMBER OF BLOOD DONATIONS TO PROPEL MARKET GROWTH
TABLE 40 BLOOD GROUP TYPING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
9.5 CLINICAL LABORATORIES
9.5.1 GROWING PREVALENCE OF BLOOD DISORDERS TO BOLSTER GROWTH
TABLE 41 BLOOD GROUP TYPING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 42 BLOOD GROUP TYPING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 BLOOD GROUP TYPING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 43 BLOOD GROUP TYPING MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: BLOOD GROUP TYPING MARKET SNAPSHOT
TABLE 44 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Increasing prevalence of chronic conditions to drive market growth
TABLE 49 ESTIMATED NUMBER OF SINGLE ORGAN TRANSPLANTS PERFORMED IN US
TABLE 50 US: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 51 US: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 52 US: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 53 US: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing incidence of blood cancer to boost market
TABLE 54 CANADA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 55 CANADA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 56 CANADA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 57 CANADA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 58 EUROPE: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure to drive market growth
TABLE 63 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 64 GERMANY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 65 GERMANY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 66 GERMANY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 67 GERMANY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing number of road accidents to propel market growth
TABLE 68 UK: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 69 UK: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 70 UK: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 71 UK: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising R&D expenditure in France to drive market growth
TABLE 72 FRANCE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 73 FRANCE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 74 FRANCE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 75 FRANCE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Increasing number of blood donors to favor market growth
TABLE 76 ITALY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 77 ITALY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 78 ITALY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 79 ITALY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Consolidation of laboratories in Spain to support market growth
TABLE 80 SPAIN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 81 SPAIN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 82 SPAIN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 83 SPAIN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 84 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
TABLE 85 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 86 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 87 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 88 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: BLOOD GROUP TYPING MARKET SNAPSHOT
TABLE 89 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 91 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Growing public access to modern healthcare to drive market growth
TABLE 94 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 95 CHINA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 96 CHINA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 97 CHINA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 98 CHINA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 99 JAPAN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 100 JAPAN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 101 JAPAN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 102 JAPAN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Increasing private & public investments in healthcare system to drive market growth
TABLE 103 INDIA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 INDIA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 105 INDIA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 106 INDIA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 107 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 108 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 109 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 110 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE TO SUPPORT MARKET GROWTH
TABLE 111 BRAZIL: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 112 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 113 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 114 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 115 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 116 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 119 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES OF KEY PLAYERS
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GROUP TYPING MARKET
TABLE 120 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD GROUP TYPING MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 31 BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER (2022)
TABLE 121 BLOOD GROUP TYPING MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022)
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 32 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT, 2022
11.6 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 33 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
11.6.5 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
TABLE 122 BLOOD GROUP TYPING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 123 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 124 COMPANY REGIONAL FOOTPRINT
TABLE 125 BLOOD GROUP TYPING MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES
TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–AUGUST 2023)
11.7.2 DEALS
TABLE 127 KEY DEALS (JANUARY 2020–AUGUST 2023)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS
12.1.1 BIO-RAD LABORATORIES, INC.
TABLE 128 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.2 QUIDELORTHO CORPORATION
TABLE 129 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
FIGURE 36 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 GRIFOLS, S.A.
TABLE 130 GRIFOLS, S.A.: BUSINESS OVERVIEW
FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 131 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 IMMUCOR, INC.
TABLE 132 IMMUCOR, INC.: BUSINESS OVERVIEW
12.1.6 QUOTIENT LIMITED
TABLE 133 QUOTIENT LIMITED: BUSINESS OVERVIEW
FIGURE 39 QUOTIENT LIMITED: COMPANY SNAPSHOT (2021)
12.1.7 DANAHER
TABLE 134 DANAHER: BUSINESS OVERVIEW
FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022)
12.1.8 MERCK KGAA
TABLE 135 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.9 NOVACYT
TABLE 136 NOVACYT: BUSINESS OVERVIEW
FIGURE 42 NOVACYT: COMPANY SNAPSHOT (2022)
12.1.10 BAG HEALTH CARE GMBH
TABLE 137 BAG HEALTH CARE GMBH: BUSINESS OVERVIEW
12.1.11 RAPID LABS LTD.
TABLE 138 RAPID LABS LTD.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AGENA BIOSCIENCE, INC.
TABLE 139 AGENA BIOSCIENCE, INC.: COMPANY OVERVIEW
12.2.2 BIOREX DIAGNOSTICS
TABLE 140 BIOREX DIAGNOSTICS: COMPANY OVERVIEW
12.2.3 HUMAN GESELLSCHAFT FЬR BIOCHEMICA UND DIAGNOSTICA MBH
TABLE 141 HUMAN GESELLSCHAFT FЬR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW
12.2.4 PRESTIGE DIAGNOSTICS
TABLE 142 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
12.2.5 DIALAB GMBH
TABLE 143 DIALAB GMBH: COMPANY OVERVIEW
12.2.6 LORNE LABORATORIES LIMITED
TABLE 144 LORNE LABORATORIES LIMITED: COMPANY OVERVIEW
12.2.7 ATLAS MEDICAL GMBH
TABLE 145 ATLAS MEDICAL GMBH: COMPANY OVERVIEW
12.2.8 TORAX BIOSCIENCES LIMITED
TABLE 146 TORAX BIOSCIENCES LIMITED: COMPANY OVERVIEW
12.2.9 FORTRESS DIAGNOSTICS
TABLE 147 FORTRESS DIAGNOSTICS: COMPANY OVERVIEW
12.2.10 AXO SCIENCE
TABLE 148 AXO SCIENCE: COMPANY OVERVIEW
12.2.11 MAXWIN HEALTH CARE PVT. LTD.
TABLE 149 MAXWIN HEALTH CARE PVT. LTD.: COMPANY OVERVIEW
12.2.12 ANAMOL LABORATORIES PVT. LTD.
TABLE 150 ANAMOL LABORATORIES PVT. LTD.: COMPANY OVERVIEW
12.2.13 J. MITRA & CO. PVT. LTD.
TABLE 151 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
12.2.14 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
TABLE 152 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 BLOOD GROUP TYPING MARKET
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 BLOOD GROUP TYPING MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 BLOOD GROUP TYPING MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 GROWTH RATE ASSUMPTIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: BLOOD GROUP TYPING MARKET
2.9 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 8 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE,
2023 VS. 2028 (USD MILLION)
FIGURE 9 BLOOD GROUP TYPING MARKET, BY TEST TYPE,
2023 VS. 2028 (USD MILLION)
FIGURE 10 BLOOD GROUP TYPING MARKET, BY TECHNIQUE,
2023 VS. 2028 (USD MILLION)
FIGURE 11 BLOOD GROUP TYPING MARKET, BY END USER,
2023 VS. 2028 (USD MILLION)
FIGURE 12 BLOOD GROUP TYPING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 BLOOD GROUP TYPING MARKET OVERVIEW
FIGURE 13 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 14 CONSUMABLES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2023 VS. 2028
FIGURE 15 ABO BLOOD TESTS & RH TYPING SEGMENT TO DOMINATE MARKET IN 2028
4.4 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2023 VS. 2028
FIGURE 16 ASSAY-BASED TECHNIQUES SEGMENT TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD
4.5 BLOOD GROUP TYPING MARKET, BY END USER, 2023 VS. 2028
FIGURE 17 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
4.6 BLOOD GROUP TYPING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN BLOOD GROUP TYPING MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 BLOOD GROUP TYPING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations
FIGURE 20 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 2015–2030 (MILLION INDIVIDUALS)
5.2.1.2 Growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions
5.2.1.3 Increasing demand for blood group typing in prenatal testing
5.2.1.4 High usage of blood group typing in forensic sciences
5.2.1.5 Extensive R&D in blood typing
5.2.1.6 Stringent regulatory standards for blood transfusion
TABLE 1 LIST OF PRODUCTS CBER REGULATES
5.2.2 RESTRAINTS
5.2.2.1 Emergence of blood alternatives
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
TABLE 2 INDICATIVE PRICING FOR BLOOD GROUP TYPING PRODUCTS
5.3.2 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS, BY KEY PLAYER
TABLE 3 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 21 PATENT ANALYSIS FOR BLOOD GROUP TYPING REAGENTS (JANUARY 2013–DECEMBER 2022)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS OF BLOOD GROUP TYPING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 23 BLOOD GROUP TYPING MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 24 BLOOD GROUP TYPING MARKET: ECOSYSTEM ANALYSIS
5.7.1 BLOOD GROUP TYPING MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 BLOOD GROUP TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY LANDSCAPE
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.5 MIDDLE EAST
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2023–2024
TABLE 13 BLOOD GROUP TYPING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 REVENUE SHIFT IN BLOOD GROUP TYPING MARKET
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS
TABLE 14 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
TABLE 15 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS
5.15.3 CASE STUDY ANALYSIS
6 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
TABLE 16 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
TABLE 17 KEY CONSUMABLES AVAILABLE IN MARKET
TABLE 18 BLOOD GROUP TYPING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 19 BLOOD GROUP TYPING CONSUMABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2.1 ANTISERA REAGENTS
6.2.1.1 Increasing demand for cost-effective blood typing solutions to support uptake of antisera reagents
TABLE 20 ANTISERA REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.2 ANTI-HUMAN GLOBULIN REAGENTS
6.2.2.1 Increasing number of organ transplantations to drive uptake of AHG reagents
TABLE 21 ANTI-HUMAN GLOBULIN REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.3 RED BLOOD CELL REAGENTS
6.2.3.1 Higher compatibility of red blood cell reagents with variety of blood group typing techniques to support uptake
TABLE 22 RED BLOOD CELL REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.2.4 BLOOD BANK SALINE
6.2.4.1 Ability of blood bank saline to preserve integrity of RBCs to support market growth
TABLE 23 BLOOD BANK SALINE MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 GROWING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST DEMAND FOR BLOOD GROUP TYPING INSTRUMENTS
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 25 BLOOD GROUP TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN MARKET SEGMENT
TABLE 26 BLOOD GROUP TYPING SERVICES & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 BLOOD GROUP TYPING MARKET, BY TEST TYPE
7.1 INTRODUCTION
TABLE 27 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
7.2 ABO BLOOD TESTS & RH TYPING
7.2.1 GROWING AWARENESS OF IMPORTANCE OF BLOOD DONATION TO DRIVE GROWTH
TABLE 28 BLOOD GROUP TYPING MARKET FOR ABO BLOOD TESTS & RH TYPING, BY REGION, 2021–2028 (USD MILLION)
7.3 ANTIBODY SCREENING
7.3.1 INCREASING INCIDENCE OF CANCER AND AUTOIMMUNE DISORDERS TO SUPPORT GROWTH
TABLE 29 BLOOD GROUP TYPING MARKET FOR ANTIBODY SCREENING, BY REGION, 2021–2028 (USD MILLION)
7.4 HLA TYPING
7.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO STIMULATE DEMAND FOR HLA TYPING
TABLE 30 BLOOD GROUP TYPING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION)
7.5 CROSS-MATCHING TESTS
7.5.1 GROWING NEED FOR BLOOD TRANSFUSION TO PROPEL MARKET GROWTH
TABLE 31 BLOOD GROUP TYPING MARKET FOR CROSS-MATCHING TESTS, BY REGION, 2021–2028 (USD MILLION)
7.6 ANTIGEN TYPING
7.6.1 INCREASING CASES OF INCORRECT BLOOD TRANSFUSION TO FUEL GROWTH
TABLE 32 BLOOD GROUP TYPING MARKET FOR ANTIGEN TYPING, BY REGION, 2021–2028 (USD MILLION)
8 BLOOD GROUP TYPING MARKET, BY TECHNIQUE
8.1 INTRODUCTION
TABLE 33 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
8.2 ASSAY-BASED TECHNIQUES
8.2.1 AUTOMATION, SENSITIVITY, OBJECTIVITY, AND ADAPTABILITY OF ASSAY-BASED TECHNIQUES TO BOOST ADOPTION
TABLE 34 BLOOD GROUP TYPING MARKET FOR ASSAY-BASED TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
8.3 PCR-BASED AND MICROARRAY TECHNIQUES
8.3.1 HIGH ACCURACY OF PCR-BASED AND MICROARRAY TECHNIQUES TO SUPPORT GROWTH
TABLE 35 BLOOD GROUP TYPING MARKET FOR PCR-BASED AND MICROARRAY TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
8.4 MASSIVELY PARALLEL SEQUENCING
8.4.1 ABILITY TO DETECT LOW-FREQUENCY ALLELES TO DRIVE DEMAND FOR MPS TECHNIQUES
TABLE 36 BLOOD GROUP TYPING MARKET FOR MASSIVELY PARALLEL SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER TECHNIQUES
TABLE 37 BLOOD GROUP TYPING MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION)
9 BLOOD GROUP TYPING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 38 BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PRIMARY NOTES
9.2.1 KEY PRIMARY INSIGHTS
9.3 HOSPITALS
9.3.1 INCREASING NUMBER OF HOSPITALS TO BOOST GROWTH
TABLE 39 BLOOD GROUP TYPING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.4 BLOOD BANKS
9.4.1 GROWING NUMBER OF BLOOD DONATIONS TO PROPEL MARKET GROWTH
TABLE 40 BLOOD GROUP TYPING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)
9.5 CLINICAL LABORATORIES
9.5.1 GROWING PREVALENCE OF BLOOD DISORDERS TO BOLSTER GROWTH
TABLE 41 BLOOD GROUP TYPING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 42 BLOOD GROUP TYPING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 BLOOD GROUP TYPING MARKET, BY REGION
10.1 INTRODUCTION
TABLE 43 BLOOD GROUP TYPING MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: BLOOD GROUP TYPING MARKET SNAPSHOT
TABLE 44 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Increasing prevalence of chronic conditions to drive market growth
TABLE 49 ESTIMATED NUMBER OF SINGLE ORGAN TRANSPLANTS PERFORMED IN US
TABLE 50 US: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 51 US: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 52 US: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 53 US: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Increasing incidence of blood cancer to boost market
TABLE 54 CANADA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 55 CANADA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 56 CANADA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 57 CANADA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 58 EUROPE: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 60 EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 61 EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure to drive market growth
TABLE 63 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
TABLE 64 GERMANY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 65 GERMANY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 66 GERMANY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 67 GERMANY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing number of road accidents to propel market growth
TABLE 68 UK: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 69 UK: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 70 UK: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 71 UK: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising R&D expenditure in France to drive market growth
TABLE 72 FRANCE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 73 FRANCE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 74 FRANCE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 75 FRANCE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Increasing number of blood donors to favor market growth
TABLE 76 ITALY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 77 ITALY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 78 ITALY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 79 ITALY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Consolidation of laboratories in Spain to support market growth
TABLE 80 SPAIN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 81 SPAIN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 82 SPAIN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 83 SPAIN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 84 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
TABLE 85 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 86 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 87 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 88 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: BLOOD GROUP TYPING MARKET SNAPSHOT
TABLE 89 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 91 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Growing public access to modern healthcare to drive market growth
TABLE 94 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 95 CHINA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 96 CHINA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 97 CHINA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 98 CHINA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 99 JAPAN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 100 JAPAN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 101 JAPAN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 102 JAPAN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Increasing private & public investments in healthcare system to drive market growth
TABLE 103 INDIA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 104 INDIA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 105 INDIA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 106 INDIA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 107 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 108 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 109 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 110 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE TO SUPPORT MARKET GROWTH
TABLE 111 BRAZIL: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
TABLE 112 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 113 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 114 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 115 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 116 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION)
TABLE 119 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 STRATEGIES OF KEY PLAYERS
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GROUP TYPING MARKET
TABLE 120 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD GROUP TYPING MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 31 BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER (2022)
TABLE 121 BLOOD GROUP TYPING MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022)
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 32 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT, 2022
11.6 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (2022)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 33 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
11.6.5 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET
TABLE 122 BLOOD GROUP TYPING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 123 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 124 COMPANY REGIONAL FOOTPRINT
TABLE 125 BLOOD GROUP TYPING MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES
TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–AUGUST 2023)
11.7.2 DEALS
TABLE 127 KEY DEALS (JANUARY 2020–AUGUST 2023)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS
12.1.1 BIO-RAD LABORATORIES, INC.
TABLE 128 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.2 QUIDELORTHO CORPORATION
TABLE 129 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW
FIGURE 36 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 GRIFOLS, S.A.
TABLE 130 GRIFOLS, S.A.: BUSINESS OVERVIEW
FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 131 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 IMMUCOR, INC.
TABLE 132 IMMUCOR, INC.: BUSINESS OVERVIEW
12.1.6 QUOTIENT LIMITED
TABLE 133 QUOTIENT LIMITED: BUSINESS OVERVIEW
FIGURE 39 QUOTIENT LIMITED: COMPANY SNAPSHOT (2021)
12.1.7 DANAHER
TABLE 134 DANAHER: BUSINESS OVERVIEW
FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022)
12.1.8 MERCK KGAA
TABLE 135 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.9 NOVACYT
TABLE 136 NOVACYT: BUSINESS OVERVIEW
FIGURE 42 NOVACYT: COMPANY SNAPSHOT (2022)
12.1.10 BAG HEALTH CARE GMBH
TABLE 137 BAG HEALTH CARE GMBH: BUSINESS OVERVIEW
12.1.11 RAPID LABS LTD.
TABLE 138 RAPID LABS LTD.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AGENA BIOSCIENCE, INC.
TABLE 139 AGENA BIOSCIENCE, INC.: COMPANY OVERVIEW
12.2.2 BIOREX DIAGNOSTICS
TABLE 140 BIOREX DIAGNOSTICS: COMPANY OVERVIEW
12.2.3 HUMAN GESELLSCHAFT FЬR BIOCHEMICA UND DIAGNOSTICA MBH
TABLE 141 HUMAN GESELLSCHAFT FЬR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW
12.2.4 PRESTIGE DIAGNOSTICS
TABLE 142 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
12.2.5 DIALAB GMBH
TABLE 143 DIALAB GMBH: COMPANY OVERVIEW
12.2.6 LORNE LABORATORIES LIMITED
TABLE 144 LORNE LABORATORIES LIMITED: COMPANY OVERVIEW
12.2.7 ATLAS MEDICAL GMBH
TABLE 145 ATLAS MEDICAL GMBH: COMPANY OVERVIEW
12.2.8 TORAX BIOSCIENCES LIMITED
TABLE 146 TORAX BIOSCIENCES LIMITED: COMPANY OVERVIEW
12.2.9 FORTRESS DIAGNOSTICS
TABLE 147 FORTRESS DIAGNOSTICS: COMPANY OVERVIEW
12.2.10 AXO SCIENCE
TABLE 148 AXO SCIENCE: COMPANY OVERVIEW
12.2.11 MAXWIN HEALTH CARE PVT. LTD.
TABLE 149 MAXWIN HEALTH CARE PVT. LTD.: COMPANY OVERVIEW
12.2.12 ANAMOL LABORATORIES PVT. LTD.
TABLE 150 ANAMOL LABORATORIES PVT. LTD.: COMPANY OVERVIEW
12.2.13 J. MITRA & CO. PVT. LTD.
TABLE 151 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
12.2.14 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.
TABLE 152 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
